$28.42
▲ +1.6% Today
as of Jul 22, 16:46 ET
Last 30 days
Recent Press Releases & News
Bicara Therapeutics Insider Sold Shares Worth $833,129, According to a Recent SEC Filing
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
Overview
52-week range
$8.48
$24
100% of range
Avg surprise (last 3)
-36.0%
Avg reaction (last 2)
-3.3%
50% positive
Latest IV / EM
88%
EM ±20.0% · $30 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Mon May 11, 2026 | Mar/2026 | $-0.93 | $-0.64 | -45.3% | -36.8% | +1.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.67 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.50 | $-0.54 | +7.4% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.68 | $-0.40 | -70.0% | — | -8.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.60 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-19.01 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-18.94 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-38.23 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.77 | -$0.50 | -54.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-60M | — | $-41M | $-32M | $-42M | — | $-21M | $-20M |
| Net income | $-56M | — | $-36M | $-27M | $-37M | — | $-17M | $-17M |
| EPS (diluted) | $-0.93 | — | $-0.67 | $-0.50 | $-0.68 | — | $-1.60 | $-19.01 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $323M | $97M | $172M | $437M | $462M | $490M | $521M | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $545M | $422M | $297M | $444M | $471M | $503M | $522M | — |
| Total assets | $554M | $431M | $425M | $454M | $478M | $510M | $524M | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $40M | $30M | $22M | $18M | $19M | $18M | $15M | — |
| Total equity | $514M | $401M | $403M | $435M | $459M | $492M | $510M | $-175M |